Command Palette

Search for a command to run...

Clinical Trials · NCT01382589

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo

CompletedPhase 2Afamelanotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Clinuvel Pharmaceuticals Limited
Enrollment
15
Start date
Sep 2011
Locations
See registry
Primary endpoint
To compare the efficacy of afamelanotide implants and NB-UVB light in the treatment of nonsegmental vitiligo
View Afamelanotide compound reference